申请人:Negoro Kenji
公开号:US20100267775A1
公开(公告)日:2010-10-21
A pharmaceutical agent having GPR40 receptor agonistic action, particularly a compound which is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus. The present inventors have examined a compound having GPR40 receptor agonistic action, confirmed that an oxadiazolidinedione compound which has a substituent such as a benzyl group, etc. linked with a substituent such as a phenyl group, etc. through a linker at the 2-position of an oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof has an excellent GPR40 agonistic activity, and thus completed the invention. The oxadiazolidinedione compound has excellent insulin secretagogue action and anti-hyperglycemic action, and therefore can be used as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.
一种具有GPR40受体激动作用的药物,特别是一种可用作胰岛素分泌剂或预防和/或治疗糖尿病的药物。本发明人研究了一种具有GPR40受体激动作用的化合物,确认了一种氧杂二唑烷环的2位上有一个连接着苯基等取代基的连接基的苯甲基等取代基的氧杂二唑烷酮化合物,或其药学上可接受的盐具有优异的GPR40激动活性,从而完成了本发明。氧杂二唑烷酮化合物具有优异的胰岛素分泌剂作用和抗高血糖作用,因此可用作胰岛素分泌剂或预防和/或治疗糖尿病的药物。